Estradiol and Migraine: Why the Route Decides

The stroke risk with oral estrogen comes from the same first-pass mechanism that raises clot risk: estrogen swallowed goes to the liver first and shifts clotting factors. Transdermal estradiol bypasses that. The patch and clot risk page sets out the evidence for venous clots; for stroke, the picture is similar though less complete.

The clearest data come from the UK's General Practice Research Database: oral estrogen was associated with a higher stroke risk, and transdermal estradiol at standard strengths was not. On that basis, the Menopause Society and the British Menopause Society both say that migraine — with or without aura — is not a contraindication to hormone therapy, and that transdermal estradiol is the route to use.

The practical rule at ACT 2: a woman with any history of migraine is offered transdermal estradiol — the patch, gel or cream — and not oral. A woman with migraine with aura is offered it with a clear explanation of why, and with the rest of her stroke-risk picture — blood pressure, smoking, lipids, Lp(a) — measured and managed alongside.

The other half of the story is that perimenopause frequently makes migraine worse before it makes it better, and estradiol is part of the reason in both directions.

Migraine in women is often triggered by falling estrogen — the drop before a period, the drop after childbirth. Perimenopause is years of erratic estrogen with sharp, unpredictable drops, and for many women that means more frequent and more severe attacks in their mid-to-late forties. After menopause, when estrogen is low but steady, migraine often improves, and for some women disappears.

Which means that steady estradiol — transdermal, continuous, avoiding the peaks and troughs — can reduce migraine frequency in perimenopause rather than provoke it. That is the opposite of the old warning, and it is one of the reasons the route matters: a patch delivers steady levels, while oral estrogen produces a daily rise and fall that can itself act as a trigger.

It is not universal. Some women find any hormonal change worsens their migraine, and for them the plan is adjusted or reconsidered. That is what the first months of monitoring are for.

Whether the migraine comes with aura, and what the aura is — because "aura" gets used loosely and the distinction matters. Whether attacks track the menstrual cycle. Smoking status and blood pressure, because they multiply the stroke risk aura carries. Any prior clot or stroke, which changes the conversation entirely. And what migraine treatment is already in use, because triptans and some preventives have their own interactions to note.

Then the baseline panel, the transdermal route, and a specific request: keep a migraine diary through the first three months, so that "better," "worse" or "no change" is a record rather than an impression.